This article is cited by
-
A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1)
Blood Cancer Journal (2021)
-
Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma
Blood Cancer Journal (2020)